Add like
Add dislike
Add to saved papers

Urinary β2-microglobulin and disease activity in patients with tubulointerstitial nephritis and uveitis syndrome.

BACKGROUND: Urinary β2-microglobulin (Uβ2M) is elevated in tubulointerstitial nephritis and uveitis (TINU) syndrome and has emerged as an important diagnostic tool. This study aims to determine whether Uβ2M correlates with uveitis activity in TINU.

METHODS: Retrospective observational case series of nine patients with TINU and ≥ 30 days follow-up. Presenting symptoms, visual acuity, uveitis characteristics, follow-up, Uβ2M, serum creatinine (SCr), urinalysis, and renal biopsy results were collected.

RESULTS: A correlation between Uβ2M and anterior chamber (AC) cell (r = 0.69, 95% CI 0.46-0.84), flare (r = 0.65, 95% CI 0.39-0.81), trended toward a stronger correlation than SCr and AC cell (r = 0.59, 95% CI 0.29-0.79), flare (r = 0.52, 95% CI 0.19-0.75). Uβ2M decreased over 1-2 years while SCr returned to normal within a few months.

CONCLUSIONS: Uβ2M correlate with uveitis activity and trend down over the course of TINU. Uβ2M may serve as a useful tool in determining where patients are in their systemic disease course.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app